2N3 Stock Overview
Engages in the management and operation of health establishments. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
LNA Santé SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.25 |
| 52 Week High | €27.20 |
| 52 Week Low | €17.28 |
| Beta | 0.77 |
| 11 Month Change | -0.43% |
| 3 Month Change | -10.23% |
| 1 Year Change | 15.67% |
| 33 Year Change | -53.45% |
| 5 Year Change | -52.26% |
| Change since IPO | -56.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2N3 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -6.8% | -0.3% | -0.4% |
| 1Y | 15.7% | 14.5% | 7.1% |
Return vs Industry: 2N3 exceeded the German Healthcare industry which returned 14.5% over the past year.
Return vs Market: 2N3 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| 2N3 volatility | |
|---|---|
| 2N3 Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2N3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2N3's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 7,835 | Willy Siret | www.lna-sante.com |
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
LNA Santé SA Fundamentals Summary
| 2N3 fundamental statistics | |
|---|---|
| Market cap | €242.34m |
| Earnings (TTM) | €23.84m |
| Revenue (TTM) | €762.03m |
10.2x
P/E Ratio0.3x
P/S RatioIs 2N3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2N3 income statement (TTM) | |
|---|---|
| Revenue | €762.03m |
| Cost of Revenue | €513.70m |
| Gross Profit | €248.34m |
| Other Expenses | €224.50m |
| Earnings | €23.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.33 |
| Gross Margin | 32.59% |
| Net Profit Margin | 3.13% |
| Debt/Equity Ratio | 134.3% |
How did 2N3 perform over the long term?
See historical performance and comparison